Stoke Therapeutics (STOK) Soars 7.04% on Jefferies Buy Rating

Stoke Therapeutics (STOK) surged 7.04% today, marking its third consecutive day of gains, with a cumulative increase of 12.51% over the past three days. The share price reached its highest level since November 2024, with an intraday gain of 17.41%.

The strategy of buying STOK shares after they reach a recent high and selling them one week later delivered moderate returns but underperformed the benchmark. The strategy achieved a 50.98% return, while the benchmark returned 58.03%, resulting in an excess return of -7.05%. The strategy's CAGR was 17.79%, with a maximum drawdown of 0.00% and a Sharpe ratio of 0.22, indicating a low-risk approach with minimal losses during market downturns.

Jefferies initiated coverage of Stoke Therapeutics (STOK) with a "Buy" rating and a price target of $30 on July 18, 2025. This rating reflects optimism about the company's risk/reward profile, particularly in relation to its late-stage developments. Additionally, Jefferies sees a $1 billion+ opportunity for Stoke Therapeutics in the rare epilepsy drug market. These factors are likely contributing to positive investor sentiment and potentially affecting STOK's stock price.